Skip to main content
 

Investors & Media

Corporate Profile
At WAVE Life Sciences, we are driven by an unwavering passion and commitment to deliver on our mission of confronting challenging diseases by developing transformational therapies and empowering patients. We are utilizing our innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare and other serious genetically defined diseases. Given the versatility of our chemistry platform, WAVE’s deep, diverse pipeline spans multiple modalities including antisense, exon-skipping, and single-stranded RNAi.
Recent News
October 12, 2017
Wave Life Sciences to Present at the Jefferies Gene Technology Investor Summit
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 12, 2017-- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will present at the Jefferies Gene Technology Investor Summit on Thursday, October 12, 2017 at 8:20 A.M. ET in New York, New York. A live web... 
August 22, 2017
Wave Life Sciences Announces Publication of Paper in Nature Biotechnology Establishing the Importance of Stereochemical Purity in Oligonucleotide Drug Design
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 22, 2017-- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced the publication of a new paper in the September issue of Nature Biotechnology. The paper describes a breakthrough method to produce antisense oligonucleotide (ASO) therapeutics with high stereochemical purity as well... 
August 9, 2017
Wave Life Sciences Reports Second Quarter 2017 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 9, 2017-- Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced financial results for the second quarter ended June 30, 2017. “We recently achieved two major milestones: transitioning to a clinical stage company, with the commencement of our two phase 1b/2a trials in Hunt... 

view all

Upcoming Events
There are currently no events scheduled.

view all